Clinical Trial Update: A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Xevinapant in combination with platinum-based chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the head an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Xevinapant (Debio 1143) (xevinapant)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Status: TERMINATED | Results posted: 2025-10-08